IVIG and HLA Antibodies. Evidence for Inhibition of Complement Activation but Not for Anti‐Idiotypic Activity

This publication has 16 references indexed in Scilit:

• Human Leukocyte Antigen Antibodies and Human Complement Activation: Role of IgG Subclass, Specificity, and Cytotoxic Potential
  Transplantation, 2004
• Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients1
  Transplantation, 2003
• Overcoming a Positive Crossmatch in Living‐Donor Kidney Transplantation
  American Journal of Transplantation, 2003
• F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins
  Nature Medicine, 2003
• Desensitization and Subsequent Kidney Transplantation of Patients Using Intravenous Immunoglobulins (IVIg)
  American Journal of Transplantation, 2002
• Cytomegalovirus immune globulin intravenous (human) administration modulates immune response to alloantigens in sensitized renal transplant candidates
  Clinical and Experimental Immunology, 2000
• INTRAVENOUS IMMUNOGLOBULIN SUPPRESSION OF HLA ALLOANTIBODY IN HIGHLY SENSITIZED TRANSPLANT CANDIDATES AND TRANSPLANTATION WITH A HISTOINCOMPATIBLE ORGAN
  Transplantation, 1994
• SUPPRESSION OF HLA-SPECIFIC ALLOANTIBODIES BY HIGH-DOSE INTRAVENOUS IMMUNOGLOBULINS (IVIg)
  Transplantation, 1993
• The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues
  Clinical Immunology and Immunopathology, 1992
• Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model.
  Journal of Clinical Investigation, 1989